NEW YORK (GenomeWeb News) – Becton Dickinson today announced that it has received US Food and Drug Administration clearance to market its new assay for detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus DNA directly from nasal swabs.

The BD Max StaphSR Assay is for use on the BD Max System, a fully automated molecular diagnostic platform, and can detect mecA dropout mutants and other new strains of MRSA that may not be detected by other assays, said BD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

At her blog, Sally Rockey dives into National Institutes of Health funding data.